By Callum Keown and Janet H. Cho
What is going on with Oracle stock?
The software sector has enjoyed a rebound recently and Wall Street analysts have rarely been as bullish on Oracle as they are now.
On Monday, the stock closed up 2.49%, at $143.76, snapping a nine-day losing streak to post its largest percent increase since June 15, when it rose 4.62%, according to Dow Jones Market Data.
Shares traded as high as $145.62 intraday, up 3.8% at the intraday high.
Before Monday, the stock had fallen for nine consecutive days, dropping 24% over that period — its longest losing streak since December 2021.
Oracle's bad run goes even further back. Since closing at a 2026 high of $248.15 on June 1, the stock has fallen on 18 out of 22 trading days. The word 'slump' is often overused but that's a proper slump. Oracle stock is down 26.2% this year and down 38.1% over the past 52 weeks. It's down 56.2% from its all-time closing high of $324.33 on Sept. 10, 2025.
What makes it even more concerning is that Oracle's latest losing streak has coincided with a software rebound. The iShares Expanded Tech-Software Sector exchange-traded fund is on a five-day winning streak through Thursday, up more than 10% over that period.
Wall Street analysts believe in the stock; 84% of those covering the shares rate them as Buy, according to FactSet data. Only once in the past 20 years, briefly in May 2011, has the stock had a higher percentage Buy rating.
The average price target of $254.84 implies an 82% upside to Thursday's closing price.
Mizuho's Siti Panigrahi is one of the most bullish, with a price target of $320. In fact, Oracle is one of Mizuho's top picks. "Oracle's end to end AI stack across database, infrastructure, and applications positions it as a key long-term beneficiary of AI adoption," Panigraghi said in a note Thursday.
However, he added that Oracle will likely need outside financing to fund its capex spending. He also listed "financing challenges" as a key risk.
The company's spending and its debt pile are likely to be the major areas of concern for investors, and a big reason for its underperformance.
But KeyBanc analysts hiked their estimates on the company last month as they have become "increasingly comfortable" that operating expense growth will remain muted. "This is where future upside will come from," they added, maintaining an Overweight rating and a $300 price target.
Write to Callum Keown at callum.keown@dowjones.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.